Publications by authors named "Bob G Schultz"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

121,616

Total Likes

3,474

Extended Reach

419,133

Social Features

39
T
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Denise K Patten, Bob G Schultz, Daniel J Berlau

Pharmacotherapy· March 2018

Videos about Article: user user

2 8 14 29 1 1 1 3

View All Article and Social Media Activity
T
The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms.
Bob G Schultz, Denise K Patten, Daniel J Berlau

Transl Neurodegener· February 2018

Videos about Article: user user user

3 3 20 11

View All Article and Social Media Activity
L
Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years.
William R Lumry, Mark Davis-Lorton, Daniel Soteres, Lucy Earl, Kieran Wynne-Cattanach, Bob G Schultz

Int Arch Allergy Immunol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary angioedema: Patient health care experiences within underrepresented racial and ethnic groups in the United States.
Timothy Craig, Alan P Baptist, John Anderson, Rafael H Zaragoza-Urdaz, Autumn F Burnette, Bob G Schultz

Ann Allergy Asthma Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis.
Nicole Princic, Kristin A Evans, Chintal H Shah, Krystal Sing, Salomé Juethner, Bob G Schultz

J Comp Eff Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data.
Nicole Princic, Kristin A Evans, Chintal H Shah, Krystal Sing, Salomé Juethner, Bob G Schultz

Drugs Real World Outcomes· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis.
John Anderson, Daniel Soteres, Raffi Tachdjian, Jennifer Mellor, Lucy Earl, Bob G Schultz

Allergy Asthma Proc· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study.
John Anderson, Daniel Soteres, Jennifer Mellor, Hannah Connolly, Kieran Wynne-Cattanach, Bob G Schultz

Allergy Asthma Proc· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study.
Bob G Schultz, Michael Bullano, Deepika Paratane, Krithika Rajagopalan

Transpl Infect Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
Bob G Schultz, Camille N Kotton, Ginita Jutlla, Riccardo Ressa, Tam de Lacey

J Med Virol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data.
Sepehr Farahbakhshian, Qi Fan, Bob G Schultz, Nicole Princic, Julie Park

J Med Econ· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab.
Chintal H Shah, Nicole Princic, Kristin A Evans, Bob G Schultz

J Med Econ· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors.
Miguel Escobar, Michael Bullano, Ali G Mokdad, Jorge Caicedo, Bob G Schultz

Expert Rev Hematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
Miguel Escobar, Neha Agrawal, Sagnik Chatterjee, Swastik Bhattacharya, Jorge Caicedo, Bob G Schultz

J Med Econ· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A.
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi Sacks

Expert Rev Pharmacoecon Outcomes Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France.
Mark Oppe, Bogdan Muresan, Katie Chan, Xenia Radu, Bob G Schultz

Expert Rev Pharmacoecon Outcomes Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis.
Vipul Jairath, Russell D Cohen, Edward V Loftus, Ninfa Candela, Karen Lasch, Bob G Schultz

BMC Gastroenterol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
Katharine Batt, Bob G Schultz, Jorge Caicedo, Christopher S Hollenbeak, Neha Agrawal

Curr Med Res Opin· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
Bob G Schultz, Ibrahim Diakite, John A Carter, Sonya J Snedecor, Robin Turpin

J Manag Care Spec Pharm· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management.
Bob G Schultz, Jessica Tilton, Julie Jun, Tiffany Scott-Horton, Danny Quach

Value Health· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis